The human trial of COVID-19 vaccine candidate developed by the University of Oxford and backed by AstraZeneca Plc has shown a positive result.
The researchers found their experimental COVID-19 vaccine produced a dual immune response in people aged 18 to 55.
Oxford’s vaccine is designed to reduce disease and transmission. Director at the Jenner Institute of Oxford University, Dr Adrian Hill, explains the mechanism of this vaccine “this vaccine triggers both arms of the immune system”.
The vaccine was officially known as AZD1222, prompted a protective immune response in hundreds of people who got the shot and did not prompt any serious side effects.